ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK

Regulators in three countries earlier this month green-lighted the combination of Merck’s Keytruda and Lenvima, a med Merck shares with Eisai, for certain previously treated endometrial cancer patients. And the companies are out with the expanded data that snagged them the go-aheads.